AVEO Pharmaceuticals, Inc. Tivozanib Demonstrates Progression-Free Survival of 14.8 Months in Subgroup of Patients with Advanced Kidney Cancer; Extended Duration of Treatment Continues to Highlight Favorable Tolerability Profile

CAMBRIDGE, Mass. & CHICAGO--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months. Additionally, PFS was similar between those patients who were treatment naïve, and those who had received prior therapy with cytokines and/or chemotherapy. These data are being presented today at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), abstract number 4599.

Back to news